Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
911637-19-9N[C@@H](CC(=O)N1CCc2c(nc(C(F)(F)F)nc2C(F)(F)F)C1)CN1CC(F)(F)CCC1=OZWPRRQZNBDYKLH-VIFPVBQESA-N911637-19-9DTXSID501030150CHEMBL3707235CHEBI:134731Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
BeschreibungGemigliptin is a prolyl-specific dipeptidyl aminopeptidase IV (DPP IV, DPP-4, CD26) inhibitor approved for the treatment of type 2 diabetes mellitus by the Korean Food and Drug Administration in 2012. Gemigliptin was discovered and developed by LG Life Sciences and is now the sixth DPP-4 inhibitor approved for the treatment of type 2 diabetes. At the time this review was prepared, there were no publications describing the discovery strategy and preclinical data that led to the advancement of gemigliptin to the clinic.
VerwendenGemigliptin Hydrochloride is used in biological studies as a novel dipeptidyl peptidase IV (DPP-IV) inhibitors and potential antidiabetic drug.
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…